Two natural khellactone, (+)-4′-Decanoyl-cis-khellactone (1) and (+)-3′-Decanoyl-cis-khellactone (2) were isolated from the rhizomes parts of A. purpuraefolia. Two compounds were

evaluated for in vitro antiplasmodial activities as well as their cytotoxic potential on SK-OV-3 cancer cell line cells. Compounds 1, 2 showed notable growth inhibitory activity against chloroquine-sensitive strains of Plasmodium falciparum with IC(50); values from 1.5 and 2.4 mu M. This compound showed no significant cytotoxicity (IC(50) > 100 mu M) evaluated using SK-OV-3 cancer cell line cells. This is the first report on the antiplasmodial activity of the compounds from A. purpuraefolia. Copyright (C) 2009,John Wiley & Sons, Ltd.”
“OBJECTIVE\n\nTo confirm the recurrence-preventing GS-1101 price efficacy and safety of 18-month bacillus Calmette-Guerin (BCG) maintenance therapy for non-muscle-invasive bladder cancer.\n\nPATIENTS AND METHODS\n\nThe Ruboxistaurin solubility dmso enrolled patients had been diagnosed

with recurrent or multiple non-muscle-invasive bladder cancer (stage Ta or T1) after complete transurethral resection of bladder tumours (TURBT).\n\nThe patients were randomized into three treatment groups: a maintenance group (BCG, 81 mg, intravesically instilled once weekly for 6 weeks as induction therapy, followed by three once-weekly instillations at 3, 6, 12 and 18 months after initiation of the induction therapy), a non-maintenance group (BCG, 81 mg, intravesically instilled once weekly for 6 weeks) and an epirubicin group (epirubicin, 40 mg, intravesically instilled nine times). The primary endpoint was recurrence-free survival (RFS).\n\nRESULTS\n\nEfficacy analysis was performed for 115 of the full-analysis-set population of 116 eligible patients, including 41 maintenance group patients, 42 non-maintenance group patients and 32 epirubicin group patients.\n\nAt the 2-year median point of the overall actual follow-up period, the final cumulative

RFS rates in the maintenance, non-maintenance and epirubicin groups were 84.6%, 65.4% and 27.7%, BAY 63-2521 concentration respectively.\n\nThe RFS following TURBT was significantly prolonged in the maintenance group compared with the non-maintenance group (generalized Wilcoxon test, P = 0.0190).\n\nCONCLUSION\n\nBCG maintenance therapy significantly prolonged the post-TURBT RFS compared with BCG induction therapy alone or epirubicin intravesical therapy.”
“von Willebrand disease (VWD) is the most common inherited bleeding disorder and arises from deficiencies and/or defects in the plasma protein von Willebrand factor (VWF). VWD is classified into 6 different types, with type 1 identified as a (partial) quantitative deficiency of VWF, type 3 defined by a (virtual) total deficiency of VWF, and type 2 identifying four separate types (2A, 2B, 2M, 2N) characterised by qualitative defects.